Why blood-brain barrier penetration changes everything in MS
The fundamental therapeutic gap in progressive multiple sclerosis is anatomical: once inflammation becomes compartmentalised behind an intact blood-brain barrier, large-molecule therapies simply cannot reach it. Tolebrutinib and fenebrutinib are specifically engineered as brain-penetrant small molecules to close that gap. Tolebrutinib achieves a CSF-to-plasma partition coefficient (kp,uu) of 0.40 in non-human primates, with CSF exposure exceeding its IC₅₀ for microglia for up to 4 hours post-dose at the 60 mg therapeutic dose. Fenebrutinib achieves a 1:1 brain-to-plasma concentration ratio in preclinical models and has been detected in human CSF at therapeutically relevant levels.
This pharmacokinetic distinction is not merely academic. In progressive MS, the blood-brain barrier is largely intact at sites of smoldering inflammation—meaning that anti-CD20 monoclonal antibodies (~150 kDa), which achieve CSF concentrations of less than 0.1% of serum levels, are structurally excluded from the compartment where the most clinically relevant damage is occurring. Small-molecule BTK inhibitors, by contrast, passively diffuse across the barrier to reach CNS-resident immune cells. According to research published in Nature, this CNS accessibility is central to the mechanistic rationale for BTK inhibition in progressive MS.
Tolebrutinib achieves a CSF-to-plasma partition coefficient (kp,uu) of 0.40 in non-human primates, with CSF exposure exceeding its IC₅₀ for microglia for up to 4 hours post-dose at the 60 mg therapeutic dose. Anti-CD20 monoclonal antibodies, by contrast, achieve CSF concentrations of less than 0.1% of serum levels.
The implications extend to route of administration. Both tolebrutinib and fenebrutinib are oral, daily therapies—a meaningful practical distinction from intravenous ocrelizumab (every 6 months) or subcutaneous ofatumumab injections, particularly relevant for patients managing progressive disability.
The microglial BTK axis: 120-fold expression and smoldering lesion rims
BTK inhibitors modulate two distinct cell populations in MS: peripheral and CNS-resident B cells, and—critically—CNS-resident microglia and macrophages. BTK is expressed at 120-fold higher levels in microglia compared to other CNS cell types, and in active and chronic active MS lesions, BTK expression is significantly upregulated in microglia and macrophages concentrated within lesion rims.
Chronic active lesions—also called paramagnetic rim lesions (PRLs) or iron-rim lesions—are characterised by a rim of chronically activated microglia and macrophages surrounding a demyelinated core. They represent ongoing tissue damage that drives progressive disability independently of relapses, and are detectable on susceptibility-weighted MRI as iron-laden microglial rings. BTK expression is significantly upregulated in microglia within these rims, making them a direct pharmacological target for CNS-penetrant BTK inhibitors.
Fenebrutinib specifically blocks microglial Fc gamma receptor (FcγR) activation, reducing cytokine release, microglial clustering, and neurite damage in human brain cell systems. This dual targeting—both B-cell receptor signalling and microglial FcγR/NLRP3 inflammasome pathways—distinguishes BTK inhibition from any existing MS therapy. Inhibition of BTK in B cells reduces activation, antibody production, and pro-inflammatory cytokine release without complete B-cell depletion, allowing faster immune reconstitution compared to anti-CD20 therapies.
“BTK is expressed at 120-fold higher levels in microglia compared to other CNS cell types—and in chronic active MS lesions, expression is further upregulated precisely at the rim sites driving smoldering disability.”
BTK is expressed at 120-fold higher levels in microglia compared to other CNS cell types. In active and chronic active MS lesions, BTK expression is significantly upregulated in microglia and macrophages within lesion rims—the sites of smoldering inflammation that drive progressive disability independently of relapses.
Explore the full patent and literature landscape for BTK inhibitors in neuroinflammation with PatSnap Eureka.
Explore BTK Inhibitor Data in PatSnap Eureka →Where anti-CD20 therapies stop: peripheral depletion and the PRL problem
Anti-CD20 monoclonal antibodies—ocrelizumab, ofatumumab, rituximab—achieve profound peripheral B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis, typically eliminating more than 95% of circulating B cells for 6 months or longer. This mechanism is highly effective against relapsing MS, where peripheral immune activation and new inflammatory lesion formation are the dominant pathological processes. The limitation emerges in progressive disease.
As large monoclonal antibodies of approximately 150 kDa, anti-CD20 therapies cannot meaningfully penetrate the intact blood-brain barrier. Their primary CNS effect is indirect: depleting peripheral B cells that would otherwise traffic into the CNS, reducing antigen presentation and T-cell activation in peripheral lymphoid organs, and decreasing pro-inflammatory cytokine production peripherally. Some CNS penetration may occur at sites of blood-brain barrier disruption in acute inflammatory lesions, but this represents a minority of the pathological burden in progressive MS. According to data reviewed by MDPI‘s Journal of Clinical Medicine, ocrelizumab showed only marginal benefit in primary progressive MS in the ORATORIO trial, and efficacy diminishes in older patients and those with established disability.
Multiple studies demonstrate that paramagnetic rim lesions persist after anti-CD20 treatment, with no significant reduction in rim volume or number. While anti-CD20 therapies effectively control peripheral immune activation and new inflammatory lesion formation, they have limited capacity to modulate the chronic microglial activation and smoldering inflammation trapped behind an intact blood-brain barrier.
The persistence of paramagnetic rim lesions under anti-CD20 therapy is mechanistically coherent: the microglial activation driving rim expansion operates independently of peripheral B-cell availability once the inflammatory process is established within the CNS compartment. This is precisely the therapeutic gap that CNS-penetrant BTK inhibition is designed to address. Research published in IMR Press‘s Journal of Integrative Neuroscience underscores that T-cell and microglial contributions to progressive MS pathology operate in compartments inaccessible to peripheral immunotherapies.
Paramagnetic rim lesions persist after anti-CD20 treatment in multiple sclerosis, with no significant reduction in rim volume or number, indicating that peripheral B-cell depletion cannot modulate the chronic microglial activation that drives smoldering neuroinflammation behind an intact blood-brain barrier.
Clinical evidence: Phase 3 results across the MS spectrum
The mechanistic distinction between BTK inhibitors and anti-CD20 therapies is now translating into differentiated clinical outcomes, particularly in patient populations where peripheral immunotherapy has historically offered limited benefit.
Tolebrutinib: HERCULES trial—first positive result in non-relapsing SPMS
The Phase 3 HERCULES trial enrolled 1,131 patients with non-relapsing secondary progressive MS (nrSPMS)—a population with no approved therapies and significant unmet need, where disability accumulates independently of relapses through smoldering CNS inflammation. Tolebrutinib delayed 6-month confirmed disability progression by 31% compared to placebo (HR 0.69; 95% CI 0.55–0.88; p=0.0026). Confirmed disability improvement nearly doubled: 10% of tolebrutinib-treated patients versus 5% with placebo (HR 1.88). This represents the first positive Phase 3 trial demonstrating disability delay in non-relapsing SPMS, according to Sanofi’s press release and reporting from Cleveland Clinic.
Fenebrutinib: dual success in relapsing and primary progressive MS
Fenebrutinib demonstrated results across both relapsing MS and primary progressive MS. In the FENhance 2 trial (RMS), fenebrutinib met its primary endpoint, significantly reducing annualized relapse rate versus teriflunomide over 96 weeks. In the FENtrepid trial (PPMS), fenebrutinib was non-inferior to ocrelizumab in delaying composite confirmed disability progression over 120 weeks, with numerical benefits emerging at week 24. Phase II extension data showed near-complete disease suppression with an annualized relapse rate of 0.06—equivalent to approximately one relapse every 17 years—and no disability progression up to 48–96 weeks. These results position fenebrutinib as potentially the first high-efficacy oral therapy effective in both relapsing and primary progressive MS.
Track the fenebrutinib and tolebrutinib clinical pipeline and competitive landscape with PatSnap Eureka’s drug intelligence tools.
Analyse MS Drug Pipelines in PatSnap Eureka →Anti-CD20: strong in relapsing, modest in progressive MS
Anti-CD20 therapies remain highly effective in relapsing MS, reducing relapse rates by 45–55% and new MRI lesions by 90–95% compared to placebo or active comparators. However, their impact on disability progression independent of relapses is modest, particularly in progressive MS without active inflammation. Ocrelizumab showed only marginal benefit in primary progressive MS in the ORATORIO trial, and efficacy diminishes in older patients and those with established disability—populations where CNS-compartmentalised inflammation predominates. B-cell reconstitution after anti-CD20 therapy takes 6–12 months or longer, versus faster reconstitution with non-depleting BTK inhibition.
Comparative profile: mechanism, efficacy, and safety side by side
The mechanistic and clinical distinctions between BTK inhibitors and anti-CD20 therapies are most clearly seen in a structured comparison across the dimensions that matter most for treatment decision-making in MS. Research published by Neurotherapeutics highlights that the two therapeutic classes occupy complementary rather than competing positions across the MS spectrum.
| Dimension | BTK Inhibitors (Tolebrutinib, Fenebrutinib) | Anti-CD20 (Ocrelizumab, Ofatumumab) |
|---|---|---|
| CNS Penetration | High; bioactive CSF concentrations; kp,uu 0.40 (tolebrutinib) to 1:1 (fenebrutinib) | Minimal; <0.1% CSF vs. serum; limited to BBB-disrupted sites |
| Primary Cellular Targets | B cells + microglia/macrophages (dual targeting) | B cells only (peripheral depletion) |
| B-Cell Modulation | Inhibits activation without depletion; faster reconstitution | Complete depletion; prolonged reconstitution (6–12+ months) |
| Microglial Modulation | Direct inhibition of FcγR signalling, NLRP3 inflammasome, cytokine release | No direct microglial effect |
| Impact on Chronic Active Lesions | Potential to modulate rim inflammation and PRL activity (under investigation) | No resolution of PRLs; persistent smoldering inflammation |
| Efficacy in Relapsing MS | Significant relapse reduction (fenebrutinib positive in FENhance 2) | Strong relapse reduction (45–55% vs. placebo) |
| Efficacy in Progressive MS | First positive trial in nrSPMS (tolebrutinib 31% CDP delay); fenebrutinib non-inferior to ocrelizumab in PPMS | Modest benefit in PPMS; limited efficacy in inactive progressive MS |
| Administration | Oral, daily | IV infusion (ocrelizumab) or subcutaneous injection every 6 months |
| Safety Considerations | Liver enzyme elevations (monitoring required); non-depleting | Infusion reactions; prolonged immunosuppression; infection risk |
Regulatory trajectory and the path to approval
Tolebrutinib received FDA Breakthrough Therapy Designation in December 2024, with global regulatory submissions underway following the HERCULES results. If approved, tolebrutinib would become the first therapy specifically indicated for non-relapsing secondary progressive MS—a population with no currently approved options.
Fenebrutinib Phase 3 data from FENhance 1 (RMS) are expected in H1 2026, after which regulatory submissions will be considered. If approved, fenebrutinib would potentially be the first and only BTK inhibitor approved across both relapsing and primary progressive MS—and the first high-efficacy oral therapy spanning the full MS spectrum. As PatSnap’s innovation intelligence platform tracks across the BTK inhibitor pipeline, the IP and clinical development activity in this space has accelerated substantially since 2022.
Tolebrutinib received FDA Breakthrough Therapy Designation in December 2024 following the HERCULES Phase 3 trial, which showed a 31% reduction in 6-month confirmed disability progression in non-relapsing secondary progressive MS—the first positive Phase 3 trial in this patient population. Fenebrutinib Phase 3 data from FENhance 1 are expected in H1 2026.
The broader significance of these approvals, if realised, extends beyond the individual agents. CNS-penetrant BTK inhibitors would represent the first class of therapies designed to directly modulate smoldering neuroinflammation within the CNS compartment—addressing a pathological mechanism that has been recognised for decades but has remained therapeutically inaccessible. The PatSnap innovation intelligence platform currently tracks over 2 billion data points across global R&D, and the BTK inhibitor space in neuroinflammation represents one of the most active patent and clinical filing clusters in CNS drug development. According to pipeline analysis covered by Research and Markets, BTK inhibitor development for MS is among the most competitive therapeutic segments in neurology as of 2025.
“If approved, tolebrutinib and fenebrutinib would represent the first CNS-penetrant, microglial-targeting therapies for progressive MS—addressing a pathological mechanism that peripheral immunotherapies cannot reach.”